Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute)
Cited by 398
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906